Lunit published an August Medium article on cancer care challenges and AI applications in screening and diagnosis using the World Health Organization Global Status Report on Cancer 2026.
Public source
Publisher name
Public post
Our August Medium article is now live. On Lunit Medium, we share perspectives on the trends, technologies, and real-world experiences shaping the future of healthcare AI…
Company
Lunit
Conquer Cancer Through AI
- Industry
- Software Development
- Location
- Seoul, KR
- Company size
- 201–500 employees
About Lunit
Lunit is a leading provider of AI solutions for cancer diagnostics and therapeutics, with a mission to conquer cancer through AI. Our clinically proven AI enables healthcare providers to detect cancer earlier, make more precise treatment decisions, and improve patient outcomes — transforming how cancer is diagnosed and treated. Our technology spans the entire cancer continuum, from risk prediction and screening optimization to early detection and precision oncology. Lunit’s breast and chest imaging AI boosts diagnostic accuracy and efficiency, while our pathology AI is leveraged by leading pharmaceutical companies to drive biomarker discovery and companion diagnostics (CDx) development. Trusted by 10,000+ sites across 65+ countries, Lunit continues to redefine global standards in data-driven cancer care. Learn more about our technology and mission at www.lunit.io/en
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Lunit Cancer Screening
Lunit Cancer Screening published the latest issue of the Squeeze, which digs into evidence, context, and real-world experiences behind breast imaging conversations, including AI coworker studies, automation bias studies, AI-stream insights, and 10 considerations for a future-ready screening ecosystem.
Presence & Recognition
Lunit Oncology
Lunit Oncology will present three studies at the 2026 World Conference on Lung Cancer in Seoul, showing how AI-based pathology analysis deepens understanding of the tumor microenvironment.
Research & Knowledge
Panakeia
Panakeia published a new peer-reviewed study validating PANProfiler Breast ER, PR, and HER2 status directly from routine pathology images in collaboration with clinical partners, published in Clinical Breast Cancer.
Research & Knowledge
Optinosis
Optinosis published a whitepaper titled Leveraging Claims-Based Risk Stratification for Earlier Cancer Detection that explains how health plans can identify members at high risk for undiagnosed cancers.
Research & Knowledge
Ataraxis AI